Cue Biopharma. has filed a patent for antigen-presenting polypeptides that can modulate T cell activity. The patent includes single-chain and multimeric polypeptides, nucleic acids, and genetically modified cells. The claim describes a multimeric polypeptide with T-cell modulatory properties, including epitopes, MHC Class II polypeptides, and immunomodulatory domains. GlobalData’s report on Cue Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cue Biopharma, CAR-T cell based therapies was a key innovation area identified from patents. Cue Biopharma's grant share as of January 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
Multimeric antigen-presenting polypeptide for modulating t cell activity
See Also:
A patent application (Publication Number: US20240034767A1) describes a novel multimeric T-cell modulatory antigen-presenting polypeptide. The polypeptide consists of two components: a first polypeptide containing an epitope capable of binding to a T-cell receptor and a first major histocompatibility complex (MHC) Class II polypeptide, and a second polypeptide containing a second MHC Class II polypeptide. Both polypeptides may include immunomodulatory domains and optionally an immunoglobulin (Ig) Fc polypeptide or a non-Ig scaffold. The patent also covers a single-chain version of the polypeptide, which includes the epitope, MHC Class II a1 and a2 polypeptides, MHC Class II ß1 and ß2 polypeptides, an immunomodulatory polypeptide, and optionally an Ig Fc polypeptide or a non-Ig scaffold.
Furthermore, the patent application includes claims related to the amino acid sequences of the MHC Class II polypeptides, the structure of the immunomodulatory polypeptide, and the use of the polypeptides in detecting antigen-specific T cells, modulating T cell activity, and treating individuals. The invention also encompasses methods for delivering costimulatory polypeptides to target T cells and detecting specific T cells within a mixed population. Overall, the patent application outlines a comprehensive approach to developing and utilizing T-cell modulatory antigen-presenting polypeptides for various therapeutic and diagnostic applications.
To know more about GlobalData’s detailed insights on Cue Biopharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
